Mural Oncology (NASDAQ:MURA) Cut to “Outperform” at Raymond James

Mural Oncology (NASDAQ:MURA) was downgraded by stock analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. They currently have a $18.00 price objective on the stock.

A number of other research analysts have also weighed in on the company. Jones Trading restated a “hold” rating on shares of Mural Oncology in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Mural Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Mural Oncology Stock Performance

Shares of MURA traded down $2.30 during mid-day trading on Tuesday, reaching $1.53. The stock had a trading volume of 2,861,627 shares, compared to its average volume of 157,436. The business has a fifty day moving average of $3.91 and a 200 day moving average of $3.63. The firm has a market cap of $26.36 million, a price-to-earnings ratio of -0.17 and a beta of 3.66. Mural Oncology has a 12 month low of $2.87 and a 12 month high of $5.12.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the prior year, the company earned ($3.57) EPS. On average, research analysts forecast that Mural Oncology will post -7.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Commerce Bank bought a new stake in shares of Mural Oncology in the 3rd quarter valued at approximately $39,000. FMR LLC lifted its position in Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after buying an additional 11,423 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Mural Oncology in the 4th quarter worth about $68,000. Two Sigma Advisers LP purchased a new position in shares of Mural Oncology during the 4th quarter worth about $84,000. Finally, Bridgeway Capital Management LLC bought a new position in Mural Oncology during the 4th quarter valued at about $94,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.